ARTICLE | Clinical News
BB3: Ph II GUARD started
February 16, 2017 8:16 PM UTC
Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of car...
BCIQ Company Profiles
BCIQ Target Profiles
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)